

## Key Sanochemia Group Data

in T€

### Performance data

	Q1	Q2	Q3	Q4	2005/06	2004/05	Change as %
	2005/06	2005/06	2005/06	2005/06	2005/06	2004/05	
	Oct.05-Dec.05	Jan.06-Mar.06	Apr.06-Jun.06	Jul.06-Sep.06	Oct.05-Sep.06	Oct.04-Sep.05	
Sales revenues	7,174	9,196	6,619	7,306	30,295	28,927	5 %
<i>Sales&amp;Marketing (Human Pharmaceuticals)</i>	2,883	3,156	3,112	3,103	12,254	11,469	7 %
<i>Production</i>	4,291	3,588	3,507	4,203	15,589	17,452	-11 %
<i>R&amp;D</i>	0	2,452	0	0	2,452	4	61200 %
<i>Reconciliation</i>	0	0	0	0	0	2	-
EBITDA	1,314	2,301	1,217	1,149	5,981	7,524	-21 %
Depreciation / amortisation	-949	-993	-897	-936	-3,775	-4,034	6 %
EBIT	365	1,308	320	213	2,206	3,490	-37 %
<i>Sales&amp;Marketing (Human Pharmaceuticals)</i>	179	333	73	514	1,099	449	145 %
<i>Production</i>	1,240	739	334	970	3,283	7,561	-57 %
<i>R&amp;D</i>	-349	1,435	20	-83	1,023	-2,105	-
<i>Reconciliation</i>	-705	-1,199	-107	-1,188	-3,199	-2,415	-32 %
Financial result	1,063	-157	-2,320	2,930	1,516	4,372	-65 %
Pre-tax profit / loss	1,428	1,151	-2,000	3,143	3,722	7,862	-53 %
Net profit / loss	1,024	993	-1,729	2,669	2,957	5,648	-48 %
Earnings / losses per share	0.11	0.10	-0.17	0.25	0.29	0.56	-48 %

### Structural data

	2005/06	2004/05	Change as %
	30. 09. 2006	30. 09. 2005	
	Balance sheet total	104,583	
Tangible assets	16,277	16,567	-2 %
Intangible assets	21,650	18,570	17 %
Shareholders' equity	62,519	58,784	6 %
Equity ratio	59.8%	64.6%	-7 %

### IFRS Cash flow

	2005/06	2004/05	Change as %
	Oct.05-Sep.06	Oct.04-Sep.05	
	Cash flow from operating activities	3,770	
Cash flow from investment activity	-3,719	-14,046	74 %
Cash flow from financing activity	2,740	4,917	-44 %

Some minor changes may be due to rounding cumulative figures.

Due to the application of new IFRS guidelines, it was necessary to restate the figure of the previous year.